BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 16103743)

  • 1. Serum PDGF-AB in pleural mesothelioma.
    Filiberti R; Marroni P; Neri M; Ardizzoni A; Betta PG; Cafferata MA; Canessa PA; Puntoni R; Ivaldi GP; Paganuzzi M
    Tumour Biol; 2005; 26(5):221-6. PubMed ID: 16103743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
    Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
    Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
    Baud M; Strano S; Dechartres A; Jouni R; Triponez F; Chouaid C; Forgez P; Damotte D; Roche N; Régnard JF; Alifano M
    J Thorac Cardiovasc Surg; 2013 May; 145(5):1305-11. PubMed ID: 23072703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
    Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
    J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
    Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
    Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.
    Fusco V; Ardizzoni A; Merlo F; Cinquegrana A; Faravelli B; De Palma M; Chessa L; Nicolò G; Serra M; Capaccio A
    Anticancer Res; 1993; 13(3):683-9. PubMed ID: 8317897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of PDGF-AB and sP-selectin concentrations in relation to platelet count in patients with colorectal cancer before and after surgical treatment.
    Mantur M; Koper O; Snarska J; Sidorska A; Kruszewska-Wnorowska K
    Pol Arch Med Wewn; 2008 Jun; 118(6):345-50. PubMed ID: 18619189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant and non-malignant asbestos-related pleural and lung disease: 10-year follow-up study.
    Cvitanović S; Znaor L; Konsa T; Ivancević Z; Perić I; Erceg M; Vujović M; Vuković J; Beg-Zec Z
    Croat Med J; 2003 Oct; 44(5):618-25. PubMed ID: 14515425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor.
    Alì G; Boldrini L; Lucchi M; Mussi A; Corsi V; Fontanini G
    J Thorac Oncol; 2009 Mar; 4(3):348-54. PubMed ID: 19155997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma.
    Jennings CJ; O'Grady A; Cummins R; Murer B; Al-Alawi M; Madden SF; Mutti L; Harvey BJ; Thomas W; Kay EW
    J Thorac Oncol; 2012 Jan; 7(1):243-8. PubMed ID: 22011668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium.
    Ramael M; Buysse C; van den Bossche J; Segers K; van Marck E
    J Pathol; 1992 May; 167(1):1-4. PubMed ID: 1320670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
    Sugarbaker DJ; Wolf AS; Chirieac LR; Godleski JJ; Tilleman TR; Jaklitsch MT; Bueno R; Richards WG
    Eur J Cardiothorac Surg; 2011 Aug; 40(2):298-303. PubMed ID: 21310625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma.
    Tsirakis G; Pappa CA; Kanellou P; Stratinaki MA; Xekalou A; Psarakis FE; Sakellaris G; Alegakis A; Stathopoulos EN; Alexandrakis MG
    Hematol Oncol; 2012 Sep; 30(3):131-6. PubMed ID: 21919032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
    Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
    Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
    Gill RR; Richards WG; Yeap BY; Matsuoka S; Wolf AS; Gerbaudo VH; Bueno R; Sugarbaker DJ; Hatabu H
    AJR Am J Roentgenol; 2012 Feb; 198(2):359-63. PubMed ID: 22268178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
    Borasio P; Berruti A; Billé A; Lausi P; Levra MG; Giardino R; Ardissone F
    Eur J Cardiothorac Surg; 2008 Feb; 33(2):307-13. PubMed ID: 18164622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma.
    Kobashi Y; Matsushima T; Irei T
    Respirology; 2005 Nov; 10(5):660-5. PubMed ID: 16268922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells.
    Donnem T; Al-Saad S; Al-Shibli K; Andersen S; Busund LT; Bremnes RM
    J Thorac Oncol; 2008 Sep; 3(9):963-70. PubMed ID: 18758297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant mesothelioma in Basse-Normandie, a French population study. Descriptive analysis, prognostic factors and survival].
    Desoubeaux N; Bouvier V; Gervais R; Galateau-Salle F; Thibon P; Leplumey T; Herbert C; Lecherbonnier Y; Daviet JP; Letourneux M
    Rev Epidemiol Sante Publique; 2001 Dec; 49(6):523-9. PubMed ID: 11845101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.